Lorbrena

Risk of severe hepatotoxicity with concomitant strong CYP3A inducers. Withhold and resume (at same or reduced dose) or permanently discontinue based on severity if CNS effects occur. Monitor serum cholesterol and TGs prior to treatment, at Months 1 and 2, and periodically thereafter; withhold and resume (at same or reduced dose) based on severity, if hypercholesterolemia or hypertriglyceridemia occurs. Monitor ECG prior to treatment and periodically thereafter; withhold and resume (at same or reduced dose) if undergoing pacemaker placement; permanently discontinue if AV block recurs in patients without a pacemaker. Withhold if interstitial lung disease (ILD)/pneumonitis is suspected; permanently discontinue for treatment-related ILD/pneumonitis of any severity. Control BP prior to initiation, then monitor after 2 weeks and at least monthly thereafter; withhold and resume at reduced dose or permanently discontinue based on severity. Monitor fasting serum glucose prior to initiation and periodically thereafter; withhold and resume at reduced dose or permanently discontinue based on severity. Moderate (total bilirubin ≥1.5–3×ULN with any AST) or severe (total bilirubin >3×ULN with any AST) hepatic impairment. Severe renal impairment (CrCl 15–<30mL/min): reduce Lorbrena dose (See Adult). Embryo-fetal toxicity. Advise to use effective non-hormonal contraception during and for ≥6 months (females of reproductive potential) or ≥3 months (males w. female partners) after the last dose. Pregnancy: exclude status prior to initiation. Nursing mothers: not recommended (during and for ≥7 days after the last dose).